The Future of AI in Pharma, Diagnostics & Precision Medicine | Bill Taranto, President and Founding Partner & Dr. David Rubin, Managing Director - Merck Global Health Innovation Fund

Episode notes

Send us Fan Mail Over the last several years, artificial intelligence has transformed from a speculative concept in healthcare into one of the most heavily funded movements in pharmaceutical and biotech history. But in 2026, the conversation is changing. The question is no longer whether AI can generate molecules, analyze pathology slides, or identify patterns in clinical data. The real question is: which of these technologies can survive the complexity of biology, regulatory scrutiny, clinical validation, and real-world deployment? Today we’re joined once again by returning guest Bill Taranto, President and Founding Partner of the Merck Global Health Innovation Fund ( ), alongside Managing Director, Dr. David Rubin, who brings a deep scientific background spanning molecular biology, oncology, precision medicine, and digital health investing. Together, Bill and David sit at a unique intersection of pharma strategy, venture investing, translational science, and clinical deployment.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• Less about Models; More about ArchitecturePractical AI · on Artificial intelligence85 / 100
• Code Review Is a Taste Problem | David Poll ⁨@GitHub⁩Hangar DX Podcast · on Artificial intelligence81 / 100
• 321 | How to Build an AI App Without Coding: From Idea to App Store with Replit & Claude by Bryce Rattner KeithleyLeveraging AI · on Artificial intelligence80 / 100
• The Content Management System Landscape with Matt GarrepyRunAs Radio · on Artificial intelligence80 / 100
• Rapid Response: OpenAI’s Critterz blowback - Director Nik Kleverov on year zero for HollywoodPioneers of AI · on Artificial intelligence76 / 100
• #191 - Battling AI Fear: Storytelling, Technology, and Disruptive Change with Paul Roehrig, Chief Strategy and Marketing Officer at AscendionFinite By Clarity · on Artificial intelligence60 / 100

• Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100
• Inside the Global Biotech Ecosystem - Where Innovation Goes Next | Sara Jane Demy - Founder and CEO, Demy-Colton
• Reversing Cellular Age: The Scientist Who Helped Create iPS Cells Reveals What’s Next - Dr. Koji Tanabe, Ph.D. - Founder and CEO, I Peace Inc.
• The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart Institute
• The Hidden Heart Risk: Amgen’s Dr. Paul Burton on the Future of Preventing Heart Attacks - Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P. - Senior Vice President and Chief Medical Officer - Amgen